The present invention relates to a biomarker for predicting pancreatic cancer treatment responsiveness to a phosphatase and tensin homologue (PTEN) inhibitor and its use. Specifically, in the present invention, when the pancreatic cancer cell line is divided into a cell line in which growth, metastasis and invasion are promoted when the activity of the PTEN protein is inhibited, and a cell line in which growth, metastasis and invasion is inhibited, the PLK1 protein in the cell line exhibiting anticancer effects It was confirmed that the expression was increased. Therefore, the PLK1 protein is a biomarker for predicting pancreatic cancer treatment responsiveness to a PTEN inhibitor, and the PTEN inhibitor in pancreatic cancer in which expression of the PLK1 protein is increased may be useful as a composition for the treatment of pancreatic cancer.
展开▼
